Abstract:The metabolism and catabolism of sphingolipids is a clinically important pathway in which multiple conditions have been described, including Metachromatic Leukodystrophy, Tay-Sachs disease, Fabry disease, Niemann-Pick disease, and Krabbe disease, among others. The biosynthesis of ceramide, a key component of sphingolipids, is also recognized as a clinically significant pathway, particularly in neurological disease. Among these, Hypomyelinating Leukodystrophy due to variants in DEGS1 (MIM 615843) is a newly described condition. DEGS1 encodes delta-4-dihydroceramide desaturase (DEGS1) which catalyzes dihydroceramide into ceramide and is a key component of the de novo ceramide biosynthesis pathway. Clinical features associated with this condition include early onset progressive hypomyelinating leukodystrophy, global developmental delays, dystonia, spasticity, nystagmus, feeding difficulties, and poor survival. The cellular effects of DEGS1 deficiency include accumulation of dihydroceramides leading to activation of the Rac1-NADPH oxidase (NOX) pathway, abnormal regulation of amino acid transporters, and abnormal regulation of related sphingomyelin species and their regulatory roles within an intricate metabolic network. Inhibition of the NOX pathway in DEGS1 deficient cells and mice has been demonstrated to reduce neuronal oxidative stress, supporting the possible use of NOX inhibitors to prevent neurodegeneration, and treatment with fingolimod, a drug targeting sphingosine-1-phosphate signaling, reduced dihydroceramide accumulation in DEGS1 knockout mice with phenotypic improvement. Despite this, care for patients with this condition is currently supportive and no validated, noninvasive biomarkers have been identified to facilitate clinical trials for DEGS1 deficiency. Our case presents an analysis of the ceramide pathway and the global metabolic perturbations in an individual with this disorder and paves the way for future biomarker discovery to aid in clinical trial readiness. This case also highlights the power of paired molecular and metabolomic profiling to provide a precise diagnosis after a years-long diagnostic odyssey. We present a case of an 8 yo male with a history of intractable epilepsy, microcephaly, spastic quadriparesis, feeding difficulties, cortical visual impairment, frequent fractures, and sensorineural hearing loss. Brain MRIs revealed diffuse progressive leukodystrophy in the bilateral cerebral hemispheres, cerebral volume loss, and subtle lactate peak on spectroscopy. Exome sequencing revealed a novel homozygous variant, NM_003676.3 c.775C>T p.His259Tyr, in DEGS1. This variant has not previously been described, is absent from population controls, and located in a histidine box functional domain. To assess for perturbations in biochemical pathways due to DEGS1 deficiency, we performed untargeted metabolomic profiling in plasma, which revealed numerous biochemical abnormalities in sphingolipid metabolism, purine biosynthesis, and amino acid metabolism. Typical ceramide species (ceramide, hexosylceramides, and lactosylceramides) were absent, and downstream sphingomyelins were either absent or dramatically decreased and among the lowest levels observed in our clinical database. Further, sphingosine and sphingosine 1 phosphate, components of the ceramide salvage pathway, were absent and significantly reduced, respectively. Significant elevations of upstream substrates for DEGS1, including sphinganine-1-phosphate, multiple dihydroceramides, and dihydrosphingomyelins were observed, in addition to altered catecholamines and multiple abnormalities in amino acid metabolism. Taken together, these findings are consistent with deficiency of DEGS1 and confirm the diagnosis of DEGS1 Hypomyelinating Leukodystrophy in our patient. We present a case of an individual with a novel genetic finding in the de novo ceramide biosynthesis pathway, DEGS1, for whom biochemical characterization was able to provide a precise genetic diagnosis. This case highlights the potential of clinical metabolomic pathway screening in the diagnosis and evaluation of individuals with sphingolipidoses and related conditions. Several target therapeutic mechanisms have been proposed for this disease including substrate reduction and inhibiting NOX pathway activity. Validation and further characterization of analytes in this pathway for DEGS1 and other sphingolipidoses is an important step in clinical trial readiness for this newly described condition. Pathway screening for other individuals identified with DEGS1 variants within our Leukodystrophy Center and care network is ongoing.

Diagnosis of adenylosuccinate lyase deficiency by metabolomic profiling in plasma reveals a phenotypic spectrum.

Aromatic L-Amino Acid Decarboxylase Deficiency Diagnosed by Clinical Metabolomic Profiling of Plasma

Succinic semialdehyde dehydrogenase deficiency: review of the clinical phenotype and metabolic/genomic approach to diagnosis

Magnetic resonance imaging of the brain in adenylosuccinate lyase deficiency: a report of seven cases and a review of the literature

Clinical Metabolomics to Segregate Aromatic Amino Acid Decarboxylase Deficiency from Drug-Induced Metabolite Elevations

2-Pyrrolidinone and Succinimide As Clinical Screening Biomarkers for GABA-Transaminase Deficiency: Anti-seizure Medications Impact Accurate Diagnosis.

The need for vigilance: false-negative screening for adenylosuccinate lyase deficiency caused by deribosylation of urinary biomarkers

Clinical Metabolomic Profiling For The Diagnosis Of Neurometabolic Disorders For Global Development Delay, Seizures

Ep176: Metabolomics Reveals Measurable Perturbations in De Novo Ceramide Biosynthesis in DEGS1 Associated-Hypomyelinating Leukodystrophy - Towards a Clinically Significant Biomarker Profile

Untargeted Metabolomics As an Unbiased Approach to the Diagnosis of Inborn Errors of Metabolism of the Non-Oxidative Branch of the Pentose Phosphate Pathway.

Phosphoserine aminotransferase deficiency diagnosed by whole‐exome sequencing and LC–MS/MS reanalysis: A case report and review of literature

Untargeted Metabolomic Profiling Reveals Multiple Pathway Perturbations and New Clinical Biomarkers in Urea Cycle Disorders

Novel mutations in ADSL for Adenylosuccinate Lyase Deficiency identified by the combination of Trio-WES and constantly updated guidelines

Accelerated transsulfuration metabolically defines a discrete subclass of amyotrophic lateral sclerosis patients

Aromatic L-amino Acid Decarboxylase (AADC) deficiency: results from an Italian modified Delphi consensus

Identification of a Distinct Metabolomic Subtype of Sporadic ALS Patients

Unique plasma metabolomic signatures of individuals with inherited disorders of long-chain fatty acid oxidation

Mild/moderate phenotypes in AADC deficiency: Focus on the aromatic amino acid decarboxylase protein

Phenotypes and genotypes of mitochondrial aminoacyl‐tRNA synthetase deficiencies from a single neurometabolic clinic

A yeast-based complementation assay elucidates the functional impact of 200 missense variants in human PSAT1

Genome sequencing enables diagnosis and treatment of SLC5A6 neuropathy